Actinium Clinical Advisory Board Chair to Participate in the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Dr. Joseph Jurcic to Speak on "Targeted Alpha Particle Therapy for Hematologic Malignancies"

NEW YORK, NY -- (Marketwired) -- 11/11/14 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Joseph Jurcic, chair of the Company's Clinical Advisory Board, will present at the EORTC-NCI-AACR Symposium on Thursday, November 20th, 2014 at 8:40 a.m. (GMT +1) at the Centre de Convencions Internacional Barcelona (CCIB) in Barcelona, Spain.

Dr. Jurcic, speaking at the Symposium on Molecular Targets and Cancer Therapeutics, will address several key areas relating to alpha-particle therapy. These include the advantages and disadvantages of targeted alpha-particle therapy, recent clinical trials using this technology for the treatment of hematologic malignancies, as well as describe the results of recent preclinical studies using alternative radioisotopes and pre-targeting strategies. 

The schedule for the session is as follows:

Date: Thursday, November 20, 2014
Time: 8:40 AM (GMT+1)
Plenary Session 4: "Antibody-Based Therapies"
Session Title: "Targeted alpha particle therapy for hematologic malignancies"

Hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2014 Symposium will bring together around 2,000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. ( is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in such statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Actinium Pharmaceuticals, Inc.
Evan Smith, CFA
VP Investor Relations and Finance
(646) 840-5442

Source: Actinium Pharmaceuticals